(Q37975254)

English

Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.

scientific article published on 30 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Seyed Moayed Alavian

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

S V Tabatabaei

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

B Behnava

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

30 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

88-93

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22239498%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Development and validation of MIX: comprehensive free software for meta-analysis of causal research data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01532.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37975254&oldid=2097575068"